This trial studies a new medicine called sacituzumab tirumotecan (Sac-TMT) for people with locally advanced or metastatic urothelial cancer, also known as bladder cancer. Researchers want to see if Sac-TMT can help patients live longer compared to other non-platinum chemotherapy options. Current treatments include chemotherapy, immunotherapy, and targeted therapy, but this trial looks for better ways to treat this type of cancer after other treatments have not worked as well.
This study is identified by NCT07419295. It is a Phase 3 trial, which means it is testing how well the treatment works and how safe it is. The trial is FDA-regulated and aims to include about 590 participants.
Who can join
Adults aged 18 and older, both men and women, can join this trial. Participants must have advanced bladder cancer that has not improved after previous treatments. They should have received specific therapies and have certain health conditions. The trial team will check to make sure everyone meets the criteria to participate.
Condition
Bladder Cancer
Age group
Adult, Older adult
Sex
All sexes
The study team makes the final call on eligibility.
What happens in the study
Participants will be randomly placed into two groups. One group will receive sacituzumab tirumotecan through an IV every two weeks. The other group will receive a choice of chemotherapy drugs like paclitaxel, docetaxel, or vinflunine every three weeks. Everyone will continue treatment until their cancer progresses or they experience unacceptable side effects.
Where
This trial is enrolling at 4 locations. Recruiting sites are listed first.
Munson Medical Center ( Site 0812)
Traverse City, Michigan
Recruiting
The West Clinic, P.C. ( Site 0791)
Germantown, Tennessee
Recruiting
Thompson Cancer Survival Center ( Site 0803)
Knoxville, Tennessee
Recruiting
TriHealth Cancer Institute-Good Samaritan Hospital ( Site 0822)
Directs translational prostate cancer research, MSK. Treats prostate cancer, bladder cancer, testicular cancer and penile cancer. Also treats kidney cancer.
Led global trials in liver and bile duct cancer. Treats pancreatic cancer, gallbladder cancer, bile duct cancer and liver cancer. Offers targeted therapy.
Directs genitourinary oncology at Huntsman Cancer Institute. Treats pancreatic cancer, liver cancer, gallbladder cancer and esophageal cancer. Also treats stomach cancer and colorectal cancer.